摘要
Studies have shown that nonalcoholic fatty liver disease (NAFLD) is strongly associated with several metabolic disorders and diseases,such as obesity,type 2 diabetes mellitus,and dyslipidemia.In NAFLD,dyslipidemia is manifested as increased serum triglyceride and low-density lipoprotein cholesterol levels and decreased high-density lipoprotein cholesterol levels,all of which are key risk factors for cardiovascular disease (CVD).CVD is a leading cause of mortality in NAFLD patients.Thus,implementation of an aggressive therapeutic strategy for dyslipidemia with hypolipidemic agents may mitigate the risk for CVD among NAFLD patients.Here,we provide a current review of literature regarding NAFLD,with particular emphasis on dyslipidemia and available treatment options.
Studies have shown that nonalcoholic fatty liver disease (NAFLD) is strongly associated with several metabolic disorders and diseases,such as obesity,type 2 diabetes mellitus,and dyslipidemia.In NAFLD,dyslipidemia is manifested as increased serum triglyceride and low-density lipoprotein cholesterol levels and decreased high-density lipoprotein cholesterol levels,all of which are key risk factors for cardiovascular disease (CVD).CVD is a leading cause of mortality in NAFLD patients.Thus,implementation of an aggressive therapeutic strategy for dyslipidemia with hypolipidemic agents may mitigate the risk for CVD among NAFLD patients.Here,we provide a current review of literature regarding NAFLD,with particular emphasis on dyslipidemia and available treatment options.
